Finance

Lists
LKFT:AMS
Lakefront Biotherapeutics NV
€24.16
+1.09%
(+0.26) 1D
Aug 17, 5:35:26 PM GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for LKFT...
Open
€23.90
High
€24.22
Low
€23.76
Mkt. cap
1.58B
Avg. vol.
88.58K
Volume
63.49K
52-wk high
€27.12
52-wk low
€22.32
No. of employees
452
Open
€23.90
High
€24.22
Low
€23.76
Mkt. cap
1.58B
Avg. vol.
88.58K
Volume
63.49K
52-wk high
€27.12
52-wk low
€22.32
No. of employees
452
Profile
Lakefront Biotherapeutics is a Belgian pharmaceutical research company which was founded in 1999. Its headquarters are located in Mechelen and has additional locations in Leiden, Romainville, Basel, Milan, Madrid, Boston and Zagreb. The company develops drugs against rheumatoid arthritis, Crohn's disease, ulcerative colitis, psoriasis, systemic lupus erythematosus and cystic fibrosis. Wikipedia
About Lakefront Biotherapeutics NV
CEOPaul Stoffels | Paul Stoffels
Employees452
Founded1999
Headquarters-
SectorBiotechnology
Websitelakefrontbio.com
Previous reportsAll values in EUR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in EUR
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
71.16M
900.82M
6.48M
12.12M
Cost of goods sold
84.73M
107.97M
35.76M
34.64M
Cost of revenue
84.73M
107.97M
35.76M
34.64M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
34.55M
32.29M
35.50M
22.50M
Operating expense
28.10M
170.00K
34.42M
20.98M
Total operating expenses
112.83M
108.14M
70.18M
55.62M
Operating income
-41.67M
792.68M
-63.70M
-43.50M
Other non operating income
-51.21M
74.15M
64.90M
-57.80M
EBT including unusual items
-221.49M
783.16M
13.96M
2.04M
EBT excluding unusual items
-43.59M
835.73M
13.96M
-50.36M
Income tax expense
-17.50M
666.00K
70.00K
130.00K
Effective tax rate
7.90%
0.09%
0.50%
6.36%
Other operating expenses
-6.44M
-32.12M
-1.08M
-1.52M
Net income
-202.11M
782.15M
14.49M
2.11M
Net profit margin
-284.02%
86.83%
223.61%
17.39%
Earnings per share
-0.18
12.27
0.21
0.03
Interest and investment income
9.91M
14.94M
12.90M
12.14M
Interest expense
-
-1.03M
-137.00K
-
Net interest expenses
9.91M
13.90M
12.76M
12.14M
Depreciation and amortization charges
-
-
-
-
EBITDA
-33.23M
800.91M
-55.48M
-35.27M
Gain or loss from assets sale
23.83M
-1.06M
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps